Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05501327 · ClinicalTrials.gov registry record · Phase 2

Dose Regimen Study of SLI-F06 in Healthy Volunteers

A Phase 2 study of Scar and Wound Healing, sponsored by Scarless Laboratories.

Recruiting
Registry status
Phase 2
Development phase
30
Enrollment target
2
Study locations

NCT05501327 is a Phase 2 study of Scar and Wound Healing that is actively recruiting participants, run by Scarless Laboratories. The registered enrollment target is 30 participants, below the 47-participant average among 15 other Scar trials with a reported enrollment target (36% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05501327, a Phase 2 study of Scar and Wound Healing, is actively recruiting participants, sponsored by Scarless Laboratories.

RECRUITING
Registry status
Phase 2
Development phase
30 participants
Enrollment target
2
Study locations

Study Summary

Multi-center, dose-regimen, double-blind study evaluating the safety and efficacy of 4 doses of SLI-F06 compared with vehicle for improvement in scar appearance

Conditions Studied

Interventions

  • DRUG SLI-F06

Study Locations (2)

California

  • California Dermatology & Clinical Research Institute - Encinitas

Texas

  • DermResearch - Austin

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2022-07-25
Est. Completion 2024-10-25
Phase Phase 2

Sponsor

Scarless Laboratories

2 total trials

What the Registry Record Tells You About NCT05501327

The ClinicalTrials.gov registry entry for NCT05501327 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 47-participant average among 15 other Scar trials with a reported enrollment target (36% lower). The listed sponsor is Scarless Laboratories, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Scar appearing as the primary indexed condition, and to 1 intervention - of which SLI-F06 is the first listed.

NCT05501327 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Texas.

Frequently Asked Questions

What is clinical trial NCT05501327 about?

NCT05501327 is a clinical study titled "Dose Regimen Study of SLI-F06 in Healthy Volunteers". Multi-center, dose-regimen, double-blind study evaluating the safety and efficacy of 4 doses of SLI-F06 compared with vehicle for improvement in scar appearance

What is the current status of trial NCT05501327?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2022-07-25. Estimated completion is 2024-10-25.

What conditions does trial NCT05501327 study?

This clinical trial studies the following conditions: Scar, Wound Healing.

What interventions are being tested in trial NCT05501327?

The interventions under investigation include: SLI-F06 (DRUG).

Who is sponsoring clinical trial NCT05501327?

This trial is sponsored by Scarless Laboratories, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05501327 being conducted?

This trial has 2 study locations across California, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Scar

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.